

Cat. No. MHC-HM492TC

Description

| | |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Source | Recombinant APC-Labeled Human HLA-C*08:01&B2M&G12D (GADGVGKSAL) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. APC-Labeled Human HLA-C*08:01&B2M&G12D (GADGVGKSAL) Tetramer is assembled by biotinylated monomer and APC-Labeled streptavidin. It contains Cys25-Ala366(HLA-C*08:01), Ile21-Met119(B2M) and GADGVGKSAL peptide. |
| Accession | AAA59688.1(HLA-C*08:01)&P61769(B2M)&GADGVGKSAL |
| Endotoxin | Less than 1 EU per µg by the LAL method. |

Formulation and Storage

| | |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Formulation | Supplied as 0.22 µm filtered solution in PBS, 200mM L-Arginine (pH 7.4). |
| Storage | Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.